alanine has been researched along with Cardiovascular Diseases in 29 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens." | 8.02 | Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. ( Darcis, G; Fombellida, K; Frippiat, F; Lecomte, M; Léonard, P; Maes, N; Meuris, C; Moutschen, M; Paquot, N; Plum, PE; Sauvage, AS; Uurlings, F; Vaira, D, 2021) |
| "Obesity is an important correlate of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels." | 7.74 | Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. ( D'Agostino, RB; Ellison, RC; Fox, CS; Hwang, SJ; Liang, TJ; Loomba, R; O'Donnell, CJ; Vasan, RS, 2008) |
| " Carnosine may be a potential therapeutic agent (neurodegenerative, metabolic, cardiovascular diseases) mainly due to its antioxidant and antiglycating activities." | 4.84 | [Carnosine--biological activity and perspectives in pharmacotherapy]. ( Zieba, R, 2007) |
| "As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens." | 4.02 | Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. ( Darcis, G; Fombellida, K; Frippiat, F; Lecomte, M; Léonard, P; Maes, N; Meuris, C; Moutschen, M; Paquot, N; Plum, PE; Sauvage, AS; Uurlings, F; Vaira, D, 2021) |
| "Obesity is an important correlate of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels." | 3.74 | Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. ( D'Agostino, RB; Ellison, RC; Fox, CS; Hwang, SJ; Liang, TJ; Loomba, R; O'Donnell, CJ; Vasan, RS, 2008) |
| "Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system." | 2.66 | A current review of COVID-19 for the cardiovascular specialist. ( Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X, 2020) |
| " We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO)." | 1.72 | Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. ( Abou Ghayda, R; Ban, K; Cargnin, S; Choi, JY; Choi, SW; Chung, SK; Dragioti, E; Go, YY; Hong, SH; Jacob, L; Jung, JW; Jung, SY; Kim, AY; Kim, MS; Kim, NK; Kostev, K; Koyanagi, A; Kronbichler, A; Lee, KH; Lee, SW; Li, H; Moon, SH; Park, SJ; Salem, JE; Shin, JI; Shin, JS; Smith, L; Solmi, M; Terrazzino, S; Tizaoui, K; Yon, DK, 2022) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "OxTrp72-apoA1 recovered from human atheroma or plasma is lipid poor, virtually devoid of cholesterol acceptor activity and demonstrated both a potent proinflammatory activity on endothelial cells and an impaired HDL biogenesis activity in vivo." | 1.40 | An abundant dysfunctional apolipoprotein A1 in human atheroma. ( Berisha, SZ; Buffa, J; Cho, L; Chuang, CC; Culley, MK; Didonato, AJ; DiDonato, JA; Fisher, EA; Fox, PL; Fu, X; Gerstenecker, GS; Gogonea, V; Gu, X; Hazen, JE; Hazen, SL; Huang, Y; Kadiyala, CS; Kim, T; Levison, BS; Li, L; Liang, S; Nguyen, TT; Parks, JS; Peng, D; Plow, EF; Schmitt, D; Smith, JD; Tang, WH; Wang, Z; Wu, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 15 (51.72) | 2.80 |
| Authors | Studies |
|---|---|
| Plum, PE | 1 |
| Maes, N | 1 |
| Sauvage, AS | 1 |
| Frippiat, F | 1 |
| Meuris, C | 1 |
| Uurlings, F | 1 |
| Lecomte, M | 1 |
| Léonard, P | 1 |
| Paquot, N | 1 |
| Fombellida, K | 1 |
| Vaira, D | 1 |
| Moutschen, M | 1 |
| Darcis, G | 1 |
| Jung, SY | 1 |
| Kim, MS | 1 |
| Li, H | 1 |
| Lee, KH | 1 |
| Koyanagi, A | 1 |
| Solmi, M | 1 |
| Kronbichler, A | 1 |
| Dragioti, E | 1 |
| Tizaoui, K | 1 |
| Cargnin, S | 1 |
| Terrazzino, S | 1 |
| Hong, SH | 1 |
| Abou Ghayda, R | 1 |
| Kim, NK | 1 |
| Chung, SK | 1 |
| Jacob, L | 1 |
| Salem, JE | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kostev, K | 1 |
| Kim, AY | 1 |
| Jung, JW | 1 |
| Choi, JY | 1 |
| Shin, JS | 1 |
| Park, SJ | 1 |
| Choi, SW | 1 |
| Ban, K | 1 |
| Moon, SH | 1 |
| Go, YY | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Sullivan, JT | 1 |
| Schafer, JJ | 1 |
| Zimmerman, M | 1 |
| Walshe, C | 1 |
| Cerankowski, J | 1 |
| Shimada, A | 1 |
| Keith, SW | 1 |
| Wan, X | 1 |
| Jia, W | 1 |
| Wang, Q | 1 |
| Chen, X | 1 |
| Wang, A | 1 |
| Zhu, L | 1 |
| Liu, X | 1 |
| Zhang, L | 1 |
| Zhuang, P | 1 |
| Jiao, J | 1 |
| Zhang, Y | 1 |
| Moreno-Vedia, J | 1 |
| Llop, D | 1 |
| Rodríguez-Calvo, R | 1 |
| Plana, N | 1 |
| Amigó, N | 1 |
| Rosales, R | 1 |
| Esteban, Y | 1 |
| Girona, J | 1 |
| Masana, L | 1 |
| Ibarretxe, D | 1 |
| Smith, JL | 1 |
| Estus, S | 1 |
| Lennie, TA | 1 |
| Moser, DK | 1 |
| Chung, ML | 1 |
| Mudd-Martin, G | 1 |
| Aggarwal, G | 1 |
| Henry, BM | 1 |
| Aggarwal, S | 1 |
| Bangalore, S | 1 |
| Lang, JP | 1 |
| Wang, X | 1 |
| Moura, FA | 1 |
| Siddiqi, HK | 1 |
| Morrow, DA | 1 |
| Bohula, EA | 1 |
| Petrakis, V | 1 |
| Panagopoulos, P | 1 |
| Papachristou, S | 1 |
| Papanas, N | 1 |
| Terzi, I | 1 |
| Trypsianis, G | 1 |
| Papazoglou, D | 1 |
| Sultan, S | 1 |
| Acharya, Y | 1 |
| Weckbach, LT | 1 |
| Kellnar, A | 1 |
| Stremmel, C | 1 |
| Stark, K | 1 |
| Kääb, S | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Gonzalez-Gay, MA | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Alvaro-Gracia, JM | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Ambrosino, I | 1 |
| Barbagelata, E | 1 |
| Corbi, G | 1 |
| Ciarambino, T | 1 |
| Politi, C | 1 |
| Moretti, AM | 1 |
| Colaco, K | 1 |
| Lee, KA | 1 |
| Akhtari, S | 1 |
| Winer, R | 1 |
| Welsh, P | 1 |
| Sattar, N | 1 |
| McInnes, IB | 1 |
| Chandran, V | 1 |
| Harvey, P | 1 |
| Cook, RJ | 1 |
| Gladman, DD | 1 |
| Piguet, V | 1 |
| Eder, L | 1 |
| Curti, ML | 1 |
| Rogero, MM | 1 |
| Baltar, VT | 1 |
| Barros, CR | 1 |
| Siqueira-Catania, A | 1 |
| Ferreira, SR | 1 |
| Rurali, E | 1 |
| Noris, M | 1 |
| Chianca, A | 1 |
| Donadelli, R | 1 |
| Banterla, F | 1 |
| Galbusera, M | 1 |
| Gherardi, G | 1 |
| Gastoldi, S | 1 |
| Parvanova, A | 1 |
| Iliev, I | 1 |
| Bossi, A | 1 |
| Haefliger, C | 1 |
| Trevisan, R | 1 |
| Remuzzi, G | 1 |
| Ruggenenti, P | 1 |
| Huang, Y | 1 |
| DiDonato, JA | 1 |
| Levison, BS | 1 |
| Schmitt, D | 1 |
| Li, L | 1 |
| Wu, Y | 1 |
| Buffa, J | 1 |
| Kim, T | 1 |
| Gerstenecker, GS | 1 |
| Gu, X | 1 |
| Kadiyala, CS | 1 |
| Wang, Z | 1 |
| Culley, MK | 1 |
| Hazen, JE | 1 |
| Didonato, AJ | 1 |
| Fu, X | 1 |
| Berisha, SZ | 1 |
| Peng, D | 1 |
| Nguyen, TT | 1 |
| Liang, S | 1 |
| Chuang, CC | 1 |
| Cho, L | 1 |
| Plow, EF | 1 |
| Fox, PL | 1 |
| Gogonea, V | 1 |
| Tang, WH | 1 |
| Parks, JS | 1 |
| Fisher, EA | 1 |
| Smith, JD | 1 |
| Hazen, SL | 1 |
| García-Broncano, P | 1 |
| Berenguer, J | 1 |
| Fernández-Rodríguez, A | 1 |
| Pineda-Tenor, D | 1 |
| Jiménez-Sousa, MÁ | 1 |
| García-Alvarez, M | 1 |
| Miralles, P | 1 |
| Aldámiz-Echevarria, T | 1 |
| López, JC | 1 |
| Micheloud, D | 1 |
| Resino, S | 1 |
| de Luis, DA | 1 |
| Ballesteros, M | 1 |
| Ruiz, E | 1 |
| Cordero, M | 1 |
| Muñoz, C | 1 |
| Penacho, MA | 1 |
| Iglesias, P | 1 |
| Lopez Guzman, A | 1 |
| Maldonado, A | 1 |
| San Martin, L | 1 |
| Puigdevall, V | 1 |
| Romero, E | 1 |
| Gonzalez Sagrado, M | 1 |
| Izaola, O | 2 |
| Conde, R | 2 |
| de Luis, D | 1 |
| Aller, R | 1 |
| Sagrado, MG | 1 |
| de la Fuente, B | 1 |
| Primo, D | 1 |
| Doney, AS | 1 |
| Fischer, B | 1 |
| Leese, G | 1 |
| Morris, AD | 1 |
| Palmer, CN | 1 |
| Rittig, K | 1 |
| Thamer, C | 1 |
| Machicao, F | 1 |
| Rietig, R | 1 |
| Stefan, N | 1 |
| Fritsche, A | 1 |
| Haring, HU | 1 |
| Balletshofer, B | 1 |
| Gomez, LC | 1 |
| Real, SM | 1 |
| Ojeda, MS | 1 |
| Gimenez, S | 1 |
| Mayorga, LS | 1 |
| Roqué, M | 1 |
| Zieba, R | 1 |
| San Miguel Hernández, A | 1 |
| Inglada-Galiana, L | 1 |
| García Iglesias, R | 1 |
| Alonso Castillejos, N | 1 |
| Martín Gil, FJ | 1 |
| Loomba, R | 1 |
| Hwang, SJ | 1 |
| O'Donnell, CJ | 1 |
| Ellison, RC | 1 |
| Vasan, RS | 1 |
| D'Agostino, RB | 1 |
| Liang, TJ | 1 |
| Fox, CS | 1 |
| Holmes, E | 1 |
| Loo, RL | 1 |
| Stamler, J | 1 |
| Bictash, M | 1 |
| Yap, IK | 1 |
| Chan, Q | 1 |
| Ebbels, T | 1 |
| De Iorio, M | 1 |
| Brown, IJ | 1 |
| Veselkov, KA | 1 |
| Daviglus, ML | 1 |
| Kesteloot, H | 1 |
| Ueshima, H | 1 |
| Zhao, L | 1 |
| Nicholson, JK | 1 |
| Elliott, P | 1 |
| Galluzzi, JR | 1 |
| Cupples, LA | 1 |
| Meigs, JB | 1 |
| Wilson, PW | 1 |
| Schaefer, EJ | 1 |
| Ordovas, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adverse Events Related to Treatments Used Against Coronavirus Disease 2019[NCT04314817] | 1,000 participants (Actual) | Observational | 2020-03-17 | Completed | |||
| A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014] | Phase 4 | 1,204 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)[NCT02783469] | 1,915 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for alanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Cardiovascul | 2020 |
A current review of COVID-19 for the cardiovascular specialist.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Card | 2020 |
Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Azithromycin; Cardiovascular Diseases; Chemicall | 2021 |
[Carnosine--biological activity and perspectives in pharmacotherapy].
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Calcium Channels; Cardiova | 2007 |
2 trials available for alanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Metabolomics strategy comprehensively unveils the effect of catechins intervention on the biomarkers of exposure to acrylamide and biomarkers of cardiometabolic risk.
Topics: Acrylamide; Adult; Alanine; Animals; Antioxidants; Aspartic Acid; Biomarkers; Capsules; Cardiovascul | 2022 |
FTO T/A and peroxisome proliferator-activated receptor-γ Pro12Ala polymorphisms but not ApoA1 -75 are associated with better response to lifestyle intervention in Brazilians at high cardiometabolic risk.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; | 2013 |
23 other studies available for alanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Heart Disease Risk Factors; HIV Infections; Human | 2021 |
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Cardiovascular Diseases; COVID-19 Drug Treatment | 2022 |
Postmarketing pharmacovigilance: Remdesivir and cardiovascular events.
Topics: Adenosine Monophosphate; Alanine; Cardiovascular Diseases; Drug-Related Side Effects and Adverse Rea | 2022 |
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; F | 2022 |
Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease.
Topics: Alanine; Atherosclerosis; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type | 2023 |
Topics: Adult; Aged; Alanine; Cardiovascular Diseases; Diet, Healthy; Female; Food Preferences; Genotype; Ha | 2020 |
Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Female; Fumarates; HIV Infections; Humans; Kidney | 2020 |
[COVID-19: a cardiological point-of-view].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Arteritis; Betacoronavirus; Cardiovascular Disea | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Gender differences in treatment of Coronavirus Disease-2019.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascul | 2020 |
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis.
Topics: Adult; Alanine; Angina Pectoris; Apolipoproteins B; Arthritis, Psoriatic; Cardiovascular Diseases; C | 2021 |
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Alanine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers | 2013 |
An abundant dysfunctional apolipoprotein A1 in human atheroma.
Topics: Alanine; Antibodies, Monoclonal; Apolipoprotein A-I; Cardiovascular Diseases; Cell Surface Display T | 2014 |
PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study.
Topics: Adult; Alanine; Amino Acid Substitution; Cardiovascular Diseases; Coinfection; Cross-Sectional Studi | 2014 |
Polymorphism Ala54Thr of fatty acid-binding protein 2: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla y Leon.
Topics: Adult; Alanine; Anthropometry; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cross-S | 2010 |
Effect of fatty acid-binding protein 2 Ala54Thr genotype on weight loss and cardiovascular risk factors after a high-polyunsaturated fat diet in obese patients.
Topics: Adult; Alanine; Caloric Restriction; Cardiovascular Diseases; Dietary Fats, Unsaturated; Fatty Acid- | 2012 |
Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study.
Topics: Age Factors; Alanine; Alleles; Amino Acid Substitution; Cardiovascular Diseases; Cohort Studies; Cyt | 2004 |
The Pro12Ala polymorphism in PPARG2 increases the effectiveness of primary prevention of cardiovascular disease by a lifestyle intervention.
Topics: Alanine; Amino Acid Substitution; C-Reactive Protein; Cardiovascular Diseases; Dietary Carbohydrates | 2007 |
Polymorphism of the FABP2 gene: a population frequency analysis and an association study with cardiovascular risk markers in Argentina.
Topics: Adult; Aged; Alanine; Argentina; Biomarkers; Cardiovascular Diseases; Fatty Acid-Binding Proteins; F | 2007 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study.
Topics: Adult; Age of Onset; Alanine; Aspartate Aminotransferases; Biomarkers; Cardiovascular Diseases; Fema | 2008 |
Human metabolic phenotype diversity and its association with diet and blood pressure.
Topics: Adult; Alanine; Animals; Blood Pressure; Cardiovascular Diseases; China; Diet; Dietary Proteins; Fem | 2008 |
Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study.
Topics: Alanine; Alcohol Drinking; Apolipoproteins E; Blood Glucose; Cardiovascular Diseases; Carrier Protei | 2001 |